Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

SynAct Pharma

14.32 SEK+8.32 %16.11. klo 18.29
Less than 1K followers

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+8.32 %
-15.76 %
-28.18 %
-1.10 %
-36.64 %
-32.61 %
+105.85 %
-88.37 %
+210.66 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Read more
Market cap
804.98M SEK
Turnover
3.24M SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Financial calendar
18.2.
2027

Annual report '26

Press release16.11.2026 klo 17.25

SynAct Pharma CEO has acquired shares in the company

SynAct Pharma
Press release16.11.2026 klo 08.00

Sten Sörensen resign from Board of Directors of SynAct Pharma

SynAct Pharma
Regulatory press release13.11.2026 klo 09.00

SynAct Pharma announces Notice of Allowance of a US patent covering the resomelagon tablet

SynAct Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release04.11.2026 klo 16.00

SynAct Pharma announces attendance and presentation at upcoming investor conferences

SynAct Pharma
Press release03.11.2026 klo 16.44

BioStock: BioVal™ analysis of SynAct’s resomelagon – three indications with a combined value of SEK 2.9B

SynAct Pharma
Press release03.11.2026 klo 16.36

SynAct Pharma announces initiation of coverage by BioVal BioStock Analytics

SynAct Pharma
Press release03.11.2026 klo 15.02

BioStock: SynAct sharpens its phase III plans for resomelagon

SynAct Pharma
Regulatory press release03.11.2026 klo 08.30

SynAct Pharma publishes Q3 2026 interim results

SynAct Pharma
Press release28.10.2026 klo 11.44

BioStock: SynAct on signing resomelagon’s first commercial partner

SynAct Pharma
Press release27.10.2026 klo 15.55

SynAct Pharma signs first commercial partnership for resomelagon with leading Brazilian pharmaceutical company

SynAct Pharma
Press release24.09.2026 klo 13.18

BioStock: Video from SynAct Pharma's presentation at BioStock Investing in Life Science 2026

SynAct Pharma
Press release24.09.2026 klo 11.56

BioStock: Video from SynAct Pharma's presentation at BioStock Investing in Life Science 2026

SynAct Pharma
Third party research22.09.2026 klo 08.09

Synact Pharma: gains WHO dengue validation for resomelagon - Edison

SynAct Pharma has received useful external validation for lead asset resomelagon’s dengue programme, with a World Health Organization (WHO)-led review published in The Lancet Microbe identifying it as one of only six candidates with sufficient efficacy...

SynAct Pharma
Press release22.09.2026 klo 08.00

SynAct Pharma to participate in investor and partnering conferences

SynAct Pharma
Press release17.09.2026 klo 17.11

BioStock: SynAct’s CSO on resomelagon making WHO’s dengue shortlist

SynAct Pharma
Press release16.09.2026 klo 12.35

WHO identifies resomelagon as one of six dengue drug candidates with evidence supporting further clinical development

SynAct Pharma
Press release10.09.2026 klo 10.00

BioStock: SynAct Pharma to Present at Investing in Life Science on September 22

SynAct Pharma
Press release07.09.2026 klo 17.30

BioStock: SynAct on phase III plans following new ADVANCE data

SynAct Pharma
Third party research07.09.2026 klo 16.12

Synact Pharma: Post-hoc analysis strengthens Phase III case - Edison

SynAct Pharma has reported further analysis of the Phase IIb ADVANCE study (testing resomelagon in rheumatoid arthritis), providing a clearer explanation for the unexpectedly strong placebo response. Management estimates that around 20% of patients entered...

SynAct Pharma
Press release07.09.2026 klo 12.00

Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development - FDA discussions on trial design planned for Q4 2026

SynAct Pharma